Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04931342 · ClinicalTrials.gov registry record · Phase 2
A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors
A Phase 2 study of Ovarian Cancer, sponsored by Hoffmann-La Roche.
- Active
- Registry status
- Phase 2
- Development phase
- 176
- Enrollment target
- 20
- Study locations
NCT04931342 is a Phase 2 study of Ovarian Cancer that is active but no longer recruiting, run by Hoffmann-La Roche. The registered enrollment target is 176 participants, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (76% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT04931342, a Phase 2 study of Ovarian Cancer, is active but no longer recruiting, sponsored by Hoffmann-La Roche.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 176 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate the efficacy and safety of multiple biomarker-selected treatments in patients with persistent or recurrent rare epithelial ovarian, fallopian tube, or primary peritoneal tumors. Enrollment will take place in two phases: a preliminary phase followed by a potential expansion phase.
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Atezolizumab
- DRUG Ipatasertib
- DRUG Cobimetinib
- DRUG Trastuzumab Emtansine
Study Locations (20)
Other
- Gynekologicko-porodnicka klinika - Prague
- CHU Besançon - Hôpital Jean Minjoz - Besançon
- Centre Francois Baclesse - Caen
- Centre Leon Berard - Lyon
- Groupe Hospitalier Diaconesses - Paris
- Centre Eugène Marquis - Rennes
- ICO - Site René Gauducheau - Saint-Herblain
- Institut Claudius Regaud - Toulouse
- Gustave Roussy - Villejuif
California
- UCSF Helen Diller Family CCC - San Francisco
Missouri
- Washington University School of Medicine - St Louis
North Carolina
- Levine Cancer Institute - Charlotte
Ohio
- Ohio State University - Columbus
Oklahoma
- University of Oklahoma Health Sciences Center - Oklahoma City
Texas
- Texas Oncology - Gulf Coast - The Woodlands
Virginia
- Virginia Oncology Associates - Norfolk
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 176 participants |
| Start Date | 2021-10-07 |
| Est. Completion | 2028-05-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04931342
The ClinicalTrials.gov registry entry for NCT04931342 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 176 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (76% lower). The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ovarian Cancer appearing as the primary indexed condition, and to 5 interventions - of which Bevacizumab is the first listed.
NCT04931342 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Other, California, Missouri.
Frequently Asked Questions
What is clinical trial NCT04931342 about?
NCT04931342 is a clinical study titled "A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors". This study will evaluate the efficacy and safety of multiple biomarker-selected treatments in patients with persistent or recurrent rare epithelial ovarian, fallopian tube, or primary peritoneal tumors. Enrollment will take place in two phases: a preliminary phase followed by a potential expansion p...
What is the current status of trial NCT04931342?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 176 participants. The study started on 2021-10-07. Estimated completion is 2028-05-30.
What conditions does trial NCT04931342 study?
This clinical trial studies the following conditions: Ovarian Cancer.
What interventions are being tested in trial NCT04931342?
The interventions under investigation include: Bevacizumab (DRUG), Atezolizumab (DRUG), Ipatasertib (DRUG), Cobimetinib (DRUG), Trastuzumab Emtansine (DRUG).
Who is sponsoring clinical trial NCT04931342?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04931342 being conducted?
This trial has 20 study locations across California, Missouri, North Carolina, Ohio, Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
RECRUITING · Phase 2
-
A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery
RECRUITING · Phase 2
-
Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer
RECRUITING · Phase 2
-
Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study)
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.